Company: CWAN
Filing Date: 2025-01-13
Form Type: 425
Source: 0001104659-25-003010
Chunk: 10

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-01-13
Form: 425
Chunk 10
---
 TRA Amendment, a copy of which is filed as Exhibit 10.1
and is incorporated by reference herein.

Item 2.02 Results of Operations and Financial Condition.

On January 13, 2024, the Company announced preliminary full year 2024
revenue of approximately $201-202 million and preliminary annual recurring revenue (ARR) as of December 31, 2024 of approximately $210-211
million.

The information in this Item 2.02 is unaudited and preliminary, and
does not present all information necessary for an understanding of the Company’s results of operations for the fiscal year ended
December 31, 2024, or financial condition as of December 31, 2024. The audit of the Company’s financial statements for the year
ended December 31, 2024 is ongoing and could result in changes to the information in this Item 2.02.

The information in this Item 2.02 is intended to be furnished and
shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On January 13, 2025, the Company and Parent issued a joint press release
announcing the execution of the Merger Agreement. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form
8-K.

The information in this Item 7.01, including Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section
18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by
reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference
in such filing.

Additional Information about the Transaction and Where to Find It

In connection with the proposed transaction,Parent will file with the SEC a registration statement on Form S-4 to register the shares of Parent
Common Stock to be issued pursuant to the transaction (the “registration statement”), which will include a proxy statement
of Enfusion and constitute a prospectus of Parent (the “joint proxy statement/prospectus”). Each of En